Lakeside Holding (LSH) announced that its recent acquisition in China, Hupan Pharmaceutical, has entered into a strategic distribution agreement with Sichuan Huiyu Pharmaceutical, a company dealing in oncology and immune-related therapies, listed on the Shanghai Stock Exchange. Hupan Pharmaceutical will distribute Huiyu Pharmaceutical’s oncology and immunotherapy drugs to hospitals and healthcare institutions to domestic and global markets. Huiyu Pharmaceutical’s flagship product, Pemetrexed Disodium for Injection, has received regulatory approvals in major markets, including China, the UK, Germany, and Finland.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LSH: